Fennec Pharmaceuticals Inc. Common Stock vs. Krystal Biotech, Inc. Common Stock
FENC
Fennec Pharmaceuticals Inc. Common Stock
$12.17 +3.93%
VS KRYSKrystal Biotech, Inc. Common Stock
$359.76 +1.00%
Fennec Pharmaceuticals Inc. Common Stock and Krystal Biotech, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| FENC | KRYS | |
|---|---|---|
| Market Cap | $410.64 million | $10.65 billion |
| Revenue (TTM) | — | $440.48 million |
| Net Income (TTM) | — | $241.47 million |
KRYS leads on 1 of 1 size & scale factors.
Valuation
| FENC | KRYS | |
|---|---|---|
| P/E Ratio | — | 45.08 |
| Price / Book | — | 7.83 |
| Price / Sales | — | 24.17 |
FENC and KRYS split the valuation factors evenly.
Profitability
| FENC | KRYS | |
|---|---|---|
| Net Margin | — | 54.82% |
| Return on Equity | — | 17.77% |
FENC and KRYS split the profitability factors evenly.
Risk & Sentiment
| FENC | KRYS | |
|---|---|---|
| Short Interest | 0.07% | 0.11% |
FENC leads on 1 of 1 risk & sentiment factors.
Dig deeper: FENC overview, FENC financials, KRYS overview, KRYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.